📊 AI Stock Rating — Summary

United Therapeutics (UTHR) reported a revenue of $799.5 million and a net income of $338.7 million for the quarter ending September 30, 2025. The company achieved an EPS of $7.73, reflecting strong cost management and profitability with a net margin of 42.4%. The firm generated a solid free cash flow of $351.6 million, underlying its robust cash generation capacity. Year-over-year revenue growth is not indicated but the substantial net margin showcases efficiency and profitability. UTHR maintains a strong balance sheet with total assets of $7.35 billion versus $760.9 million in liabilities, yielding a substantial equity base of $6.59 billion and net cash position of $1.34 billion, highlighting financial resilience. No dividends were distributed, but significant capital of $984.7 million was returned to shareholders through stock repurchases. Analyst price targets range from $447 to $587, with a consensus indicating upside potential. Despite the absence of current valuation metrics, the company's solid financial foundation and positive EPS suggest it is well-positioned for future growth and potential appreciation in stock value.

AI Score Breakdown

Revenue Growth — Score: 6/10

While specific year-over-year revenue growth figures are not provided, the $799.5 million in revenue signals a healthy operational performance. Ongoing efficiency contributes positively, though specific catalysts for revenue growth require further data.

Profitability — Score: 9/10

UTHR demonstrates strong profitability with a net income of $338.7 million and EPS of $7.73. The net margin of 42.4% underscores high operational efficiency and effective cost management.

Cash Flow Quality — Score: 8/10

The company reported a robust free cash flow of $351.6 million, reinforcing liquidity and cash-generating efficiency. Significant emphasis on buybacks enhances shareholder value, albeit with zero dividend payouts.

Leverage & Balance Sheet — Score: 9/10

UTHR maintains a strong balance sheet with negligible debt and substantial equity of $6.59 billion. The net cash position of $1.34 billion ensures high financial resilience and capacity for strategic investments.

Shareholder Returns — Score: 7/10

Significant return of capital to shareholders through $984.7 million in buybacks was notable. Despite no dividends, this suggests strong capital management. The stock's price change is not provided, but repurchase activity suggests a positive outlook.

Analyst Sentiment & Valuation — Score: 8/10

Analyst targets point to potential upside in stock price, supported by strong EPS performance. Although detailed valuation ratios are not available, the forecast suggests the stock is attractively positioned relative to recent performance.

⚠ AI-generated — informational only, not financial advice.